Autopsy report · NCT01079767

Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis

“The study treminated early according to DSMB recommendantions”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• 6 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Federation Francophone de Cancerologie Digestive

Sponsor type

University, hospital or other

Conditions

Liver Cancer

Interventions

temsirolimus

Participants

6

Sites

1

Countries

France

Trials that died the same way

• Preventing Adverse Incisional Outcomes at Cesarean Multicenter Trial
  “DSMB recommendation following interim analysis” (68% match in meaning)
• Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)
  “Recommendation by the DSMB that the study be stopped for futility” (68% match in meaning)
• Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia
  “The DSMB recommended that the study be stopped as a result of concerns regarding safety and intolerability and insufficient evidence of efficacy.” (61% match in meaning)
• A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy
  “Upon recommendation of DSMB” (60% match in meaning)
• ATG Plus Low-dose PT-Cy for GVHD Prevention
  “DSMB recommended halting the study owing to futility after the first interim analysis in August 2024.” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.